Serological testing – Page 5 – Communicable Diseases Research

The interplay of viral loads, clinical presentation, and serological responses in SARS-CoV-2 – Results from a prospective cohort of outpatient COVID-19 cases

Article

Published on 2022-04-012023-06-19
Journal: Virology [Category] COVID19(2023년), MERS, SARS,

Longitudinal profile of antibody response to SARS-CoV-2 in patients with COVID-19 in a setting from Sub-Saharan Africa: A prospective longitudinal study

사하라 사막 이남 아프리카의 상황에서 COVID-19 환자의 SARS-CoV-2에 대한 항체 반응의 종단 프로필: 전향적 종단 연구

Article

Published on 2022-03-232022-09-11
Journal: PLoS ONE [Category] MERS, SARS, 진단, 치료기술,

[키워드] African agreement antibody Antibody Response asymptomatic patient asymptomatic patients Cohort collected comprehensive evaluation COVID-19 cases COVID-19 patient detectable diagnosis of COVID-19 enrolled Enrollment epidemiological studies Factor failure Follow-up heterogeneous responses IgG IgM immunoassay implementation increase increases in lateral flow LFIAs longitudinal Longitudinal assessment median median time no difference NPV onset of symptoms Patient patients with COVID-19 PCR-confirmed COVID-19 patient plasma sample plasma samples positive Positive predictive value PPV Predictive value Prospective Study ranged reached reduced Research SARS-CoV-2 SARS-CoV-2 antibodies SARS-CoV-2 antibody scenario Seroconversion seroconversion time seroconvert seroconverted Serological testing serology Seroprevalence significantly specificity symptom onset symptomatic case symptomatic cases tested vaccine responses
[DOI] 10.1371/journal.pone.0263627 PMC 바로가기 [Article Type] Article

COVID-19 Vaccination within the Context of Reactogenicity and Immunogenicity of ChAdOx1 Vaccine Administered to Teachers in Poland

폴란드 교사에게 투여된 ChAdOx1 백신의 반응성 및 면역원성의 맥락에서 COVID-19 백신 접종

Article

Published on 2022-03-062022-09-10
Journal: International Journal of Environmental Research an [Category] MERS, SARS, 진단, 치료기술,

[키워드] adverse effects Adverse reaction Adverse reactions age All participant All participants anti-RBD Anti-RBD IgG Antibody Response ChAdOx1 ChAdOx1 vaccine ChAdOx1-S chills Context COVID-19 demonstrated detectable determinants dose dosing interval Efficacy ENhance female first dose headache immunogenicity immunologic response immunologic responses individual Infection interval malaise male mRNA multivariate logistic regression offered Older participant Participants Poland predictor RBD reactogenicity Receptor-binding domain Region reported required SARS-CoV-2 SARS-COV-2 infection Serological testing Side effect Side effects Support teacher teachers the mean the median the receptor-binding domain Tolerability uninfected Vaccine were measured
[DOI] 10.3390/ijerph19053111 PMC 바로가기 [Article Type] Article

Persistence of Immune Response in Health Care Workers After Two Doses BNT162b2 in a Longitudinal Observational Study

종단 관찰 연구에서 BNT162b2 2회 투여 후 의료 종사자의 면역 반응 지속

Observational Study

Published on 2022-03-042022-09-11
Journal: Frontiers in Immunology [Category] MERS, SARS, 임상, 진단, 치료기술,

[키워드] age All participants Analysis antibody average binding binding antibody BNT162b2 BNT162b2 vaccine booster dose booster doses booster vaccinations Care cellular Cellular immune response Course COVID-19 disease declining described detectable dose Efficacy evaluated Follow-up groups Health Health care Health care worker hospital humoral humoral and cellular immunity humoral immune response immune response immunological Immunological memory individual interferon Interferon-gamma longitudinal mRNA mRNA-based vaccine Neutralizing antibodies obesity observational study of BNT162b2 Older age participant Participants peptide peptides persistence Pfizer Quantitative response response rate resulting SARS-CoV-2 SARS-COV-2 infection second dose semi-quantitative Serological testing shown vaccination Vaccine worker
[DOI] 10.3389/fimmu.2022.839922 PMC 바로가기 [Article Type] Observational Study

Diagnostic techniques for COVID-19: A mini-review

COVID-19 진단 기술: 미니 리뷰

Review

Published on 2022-03-012022-09-11
Journal: Journal of virological methods [Category] SARS, 변종, 진단, 치료기술, 치료제,

[키워드] Accuracy antigen detection Asymptomatic carrier Asymptomatic carriers auxiliary Combination Computed tomography country COVID-19 COVID-19 diagnostic assay COVID-19 diagnostic assays COVID-19 patient COVID-19 patients CT imaging Diagnosis diagnosis of COVID-19 diagnostic diagnostics Early detection early diagnosis early stage immunological Immunological methods IMPROVE in some indicate Isolation nucleic acid nucleic acid testing nucleic acid tests pandemic positive result presence of antibody qPCR quantitative PCR reported respiratory infectious disease resulting SARS-CoV-2 SARS-CoV-2 virus Serological testing serum antibodies serum antibody Spread symptomatic patient Symptomatic patients the SARS-CoV-2 virus Viral load virus virus detection virus genome Wuhan Wuhan, China
[DOI] 10.1016/j.jviromet.2021.114437 PMC 바로가기 [Article Type] Review

Safety and immunogenicity of two recombinant DNA COVID-19 vaccines containing the coding regions of the spike or spike and nucleocapsid proteins: an interim analysis of two open-label, non-randomised, phase 1 trials in healthy adults

스파이크 또는 스파이크 및 뉴클레오캡시드 단백질의 코딩 영역을 포함하는 2개의 재조합 DNA COVID-19 백신의 안전성 및 면역원성: 건강한 성인을 대상으로 한 2개의 공개 라벨, 비무작위, 1상 시험에 대한 중간 분석

Clinical Trial

Published on 2022-03-012022-09-11
Journal: The Lancet. Microbe [Category] COVID19(2023년), MERS, SARS, 임상, 진단, 치료기술, 치료법,

[키워드] adverse event adverse events analysed Antibody Response blood sample Blood samples coding region collected COVID-19 vaccine development DNA DNA vaccine domain dose of vaccination doses drug energy ENhance enrolled fatigue first vaccination group healthy hospital humoral immunogenicity individuals induce intention-to-treat population interim analysis intervals intramuscularly Mild Ministry of Health moderate neutralising antibody response nucleocapsid nucleocapsid protein Open-label participant Participants Phase 1 phase 1 trial Plasmid plasmid DNA positive Primary outcome RBD recombinant DNA Registered reported Safe Safety SARS-CoV-2 SARS-CoV-2 spike protein SARS-CoV-2-specific T-cell responses Science screened second dose secondary outcome Serological testing South Korea Spike protein T-cell responses tested the RBD the SARS-CoV-2 the spike protein the vaccines Trade treatment-emergent adverse event Trial trial participant trials vaccination Vaccine vaccine dose vaccine immunogenicity Welfare were excluded
[DOI] 10.1016/S2666-5247(21)00358-X PMC 바로가기 [Article Type] Clinical Trial

Bacterial ligands as flexible and sensitive detectors in rapid tests for antibodies to SARS-CoV-2

SARS-COV-2에 대한 항체에 대한 빠른 시험에서 유연하고 민감한 검출기로서의 박테리아 리간드

Research Paper

Published on 2022-02-112022-09-01
Journal: Analytical and bioanalytical chemistry [Category] COVID19(2023년), Fulltext, MERS, SARS, 진단, 치료기술, 치료법,

[키워드] 95% CI Abstract Accuracy acute respiratory syndrome acute respiratory syndrome coronavirus acute respiratory syndrome coronavirus-2 addition alternatives analyzed anti-SARS-CoV-2 antibodies antibody applied Bacterial binding Broad-specific ligands cats conjugate Coronavirus-2 defined Design of experiment detectable Diagnosis diagnostic diagnostic methods diagnostic sensitivity Diseases experimental design flexibility flexible fraction gold Gold nanoparticle Gold nanoparticles human serum immune response immunoassay immunodominant Immunoglobulin Infectious diseases Lateral lateral flow immunoassay LFIA LFIAs Ligand molecular nucleocapsid protein Patient POCT point-of-care test point-of-care tests positive Protein protein A Proteins Rapid test reactivity respiratory robustness SARS-CoV-2 selective selectivity sensitivity serological Serological testing serum sample serum samples Severe acute respiratory syndrome severe acute respiratory syndrome Coronavirus severe acute respiratory syndrome coronavirus-2 Streptococcal supplementary material Typical Viral viral antigens with COVID-19
[DOI] 10.1007/s00216-022-03939-2 PMC 바로가기 [Article Type] Research Paper

SARS-CoV-2 antibodies protect against reinfection for at least 6 months in a multicentre seroepidemiological workplace cohort

SARS-CoV-2 항체는 다기관 혈청역학 작업장 코호트에서 최소 6개월 동안 재감염으로부터 보호합니다.

Multicenter Study

Published on 2022-02-102022-09-12
Journal: PLoS Biology [Category] COVID19(2023년), MERS, SARS, 진단,

Quantifying Neutralizing Antibodies in Patients with COVID-19 by a Two-Variable Generalized Additive Model

2변수 일반화 첨가제 모델을 통한 COVID-19 환자의 중화 항체 정량화

Research Article

Published on 2022-02-022022-09-10
Journal: mSphere [Category] COVID19(2023년), MERS, SARS, 바이오마커, 진단, 치료기술,

[키워드] “COVID-19 acute respiratory syndrome Additive Additive Model analyzed antibodies antibody Antibody binding Antibody titer Antibody titers approach binding binding affinity Biology biosafety biosafety level certification Clinical use Combination conventional virus neutralization test coronavirus correlation CoV COVID-19 detect disease domain Efficacy ELISA enzyme enzyme-linked immunosorbent enzyme-linked immunosorbent assay faster Generalized gold gold standard healthy donors Immunity Laboratory level 2 mathematics methodology Model neutralization test Neutralizing antibodies neutralizing antibody Neutralizing antibody titer neutralizing antibody titers Patient patients with COVID-19 PCR-confirmed Perspective platform predicted RBD Receptor-binding domain reflected regions risk SARS-CoV-2 SARS-CoV-2 antibodies SARS-CoV-2 antibody SARS-COV-2 infection SARS-CoV-2 infections SARS-CoV-2 viral Serological testing serum Severe acute respiratory syndrome Severe Acute Respiratory Syndrome CoV specimens Spike protein surrogate the binding affinity the RBD time-consuming Travel two-variable generalized additive model Vaccine vaccine efficacy Viral viral spike protein virus neutralization test with COVID-19
[DOI] 10.1128/msphere.00883-21 PMC 바로가기 [Article Type] Research Article

Serological profile of first SARS-CoV-2 reinfection cases detected within the SIREN study

SIREN 연구에서 발견된 첫 SARS-CoV-2 재감염 사례의 혈청학적 프로필

Comment

Published on 2022-02-012022-09-11
Journal: The Journal of Infection [Category] COVID19(2023년), MERS, SARS, 진단, 치료기술,

[키워드] Abstract COVID-19 COVID-19 serological testing Neutralising Antibodies Reinfection SARS-CoV-2 serological Serological testing SIREN study
[DOI] 10.1016/j.jinf.2021.09.019 PMC 바로가기 [Article Type] Comment